StudyID,Drug_Name,No_Arm,Randomization,Central_Random,Rand_Ratio,Random_Parallel,Random_Crossover,Random_Fact,Random_Cluster,Stratification,No_Stratification,Single_Arm,Hist_control,Blinding,Level_Blinding,Placebo_control,Active_Control,Control_Drug,Obj_Primary,No_Prim_EP,Primary_EP,Success_Criteria_Text,Primary_EP_SC,Key_Second_EP,Key_Second_EP_SC,IRC,Sample_Size,Power,Alpha,Sided,Subgroup,Interim,Timing_IA,Alpha_Spend_Func,Adaptive_Design,Consistency_Sens_Ana_PE,Consistency_Sens_Ana_SE,Post_Hoc_Ana,Intercurrent_Events,Gatekeeping_Strategy,Reg_Alignment,Fast_Track,Breakthrough,Priority_Review,Accelerated_App,Orphan_Drug,Pediatric,Rare_Disease,Reg_Audit,Consistency_MRCT
NCT01673867,Nivolumab; Docetaxel,2,Yes,,,Yes,No,No,,,,No,No,No,0,No,Yes,Docetaxel,,1,Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint,,,Objective Response Rate (ORR),,,,,,,,,,,,,,,,,,,,,,,,,,
